FECH

Ferrochelatase, mitochondrial · P22830 · FECH on Sugi Atlas →

29,464 patent compounds predicted against FECH, 24,845 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Erlotinib (SCHEMBL33835)	0.89	2/20
SCHEMBL185543	0.61	2/20
SCHEMBL256391	0.58	2/20
SCHEMBL245487	0.49	2/20
Gefitinib (SCHEMBL7866)	1.00	1/20
Nilotinib (SCHEMBL7901)	1.00	1/20
Erlotinib (SCHEMBL8413)	1.00	1/20
Mk-2461 (SCHEMBL93526)	1.00	1/20
Pelitinib (SCHEMBL93756)	1.00	1/20
Pelitinib (SCHEMBL93757)	1.00	1/20
Cudc-101 (SCHEMBL93769)	1.00	1/20
Cp-724714 (SCHEMBL95109)	1.00	1/20
Bgt-226 Free Base (SCHEMBL146939)	1.00	1/20
Azd-8055 (SCHEMBL298416)	1.00	1/20
Vemurafenib (SCHEMBL298931)	1.00	1/20
Ribociclib (SCHEMBL302310)	1.00	1/20
Rabusertib (SCHEMBL304747)	1.00	1/20
Rabusertib (SCHEMBL304748)	1.00	1/20
Gsk-690693 (SCHEMBL310452)	1.00	1/20
Cabozantinib (SCHEMBL360795)	1.00	1/20

Clinical trials — most relevant to FECH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies	PHASE4	COMPLETED
Supplementation With Lactoferrin in Preterm Newborns	PHASE4	COMPLETED
Iron Deficiency In Pulmonary Hypertension	PHASE4	UNKNOWN
Effect of Pioglitazone Administered to Patients With Friedreich's Ataxia: Proof of Concept	PHASE3	COMPLETED
A Pilot Clinical Trial With the Iron Chelator Deferiprone in Parkinson's Disease	PHASE2	COMPLETED
Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.	PHASE2	COMPLETED
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome	PHASE2	WITHDRAWN
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia	PHASE2	COMPLETED
Labile Iron Removal by Adding the Iron Chelator MEX-CD1 to Dialysate in Sepsis-Associated Acute Kidney Injury	PHASE1/PHASE2	RECRUITING
Methylprednisolone Treatment of Friedreich Ataxia	EARLY_PHASE1	COMPLETED
Effects of Iron Supplementation on Skeletal Muscle Properties in Females With Suboptimal Iron Storage	EARLY_PHASE1	NOT_YET_RECRUITING
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Natural History Study of FDXR Mutation-related Mitochondriopathy	nan	COMPLETED
Prognostic Value of (DHODH) Expression in (HGSOC): A Comparative Study Between Neoadjuvant and Adjuvant Chemotherapy Settings	nan	NOT_YET_RECRUITING
Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)	nan	COMPLETED
Identification of Serum Level of Glutathione Peroxidase 4	nan	NOT_YET_RECRUITING
Role of USP35 in the Detection of Ferroptosis in Juvenile Autoimmune Hepatitis	nan	NOT_YET_RECRUITING
GDF 15 in Sickle Cell Disease and Hereditary Spherocytosis	nan	UNKNOWN
Genes-in-Action - Hepcidin Regulation of Iron Supplementation	nan	COMPLETED
Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact	nan	COMPLETED
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Genomic of CONgenital Sideroblastic Anemias	nan	RECRUITING
Acetaminophen for Oxidative Stress After Cardiopulmonary Bypass	nan	COMPLETED
Defining the Functional Role of Iron in Aerobic Training and Physical Performance	nan	COMPLETED
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension	nan	COMPLETED
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum	nan	COMPLETED
Candidate Gene for Hyperferritinemia	nan	UNKNOWN
FRIEDREICH ATAXIA- STEROIDOGENESIS	nan	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a FECH binder may also engage these)

Protein	Name	Similarity
Q3YA36	—	1.000	Q3YA36 →
O57478	—	1.000	O57478 →
O42479	—	1.000	O42479 →
P22315	—	0.997	P22315 →
P22600	—	0.994	P22600 →
A2Y3Q5	—	0.990	A2Y3Q5 →
Q0DIV0	—	0.988	Q0DIV0 →
O59786	—	0.984	O59786 →
Q9V9S8	—	0.984	Q9V9S8 →
P42043	—	0.984	P42043 →
P16622	—	0.983	P16622 →
O04921	—	0.983	O04921 →
Q83H94	—	0.981	Q83H94 →
Q83FJ2	—	0.979	Q83FJ2 →
Q69TB1	—	0.978	Q69TB1 →
P42045	—	0.978	P42045 →
Q73C08	—	0.977	Q73C08 →
Q81TU9	—	0.976	Q81TU9 →
Q7UFZ7	—	0.976	Q7UFZ7 →
Q63ES4	—	0.975	Q63ES4 →
P42044	—	0.975	P42044 →
P16638	—	0.975	P16638 →
Q8FTB1	—	0.975	Q8FTB1 →
Q6HM28	—	0.975	Q6HM28 →
P11605	—	0.975	P11605 →
Q2R1U4	—	0.975	Q2R1U4 →
ACLY	ATP-citrate synthase	0.974	landscape →
P15719	—	0.974	P15719 →
B0SF60	—	0.974	B0SF60 →
Q8K370	—	0.974	Q8K370 →